"I can see why they might sell at a point in time when it needs big resources to go further."
That's the beauty of the model in place - after the intial "discovery phase" those "big resources" to advance are soley the partners responsibility. Phylogicas cash input is done & dusted.
For another little bit to wet the lips although still highly speculative --- go back to the intial partnership release in December 2009 and look at the objectives =
"Australian drug discovery company Phylogica (ASX:PYC) today announced that it has signed an agreement with Roche to evaluate Phylogicas proprietary Phylomer technology in transporting large molecules to attack disease targets within cells."
Now what is Avastin (bevacizumab) ?
Avastin is monoclonal antibody or basically a very "large" molecule...
Time will tell :-)
PYC Price at posting:
6.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)